Published in Biometrics on September 26, 2007
Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. Stat Biopharm Res (2009) 1.14
Emax model and interaction index for assessing drug interaction in combination studies. Front Biosci (Elite Ed) (2010) 0.89
Assessing interactions for fixed-dose drug combinations in tumor xenograft studies. J Biopharm Stat (2012) 0.79
Applying Emax model and bivariate thin plate splines to assess drug interactions. Front Biosci (Elite Ed) (2010) 0.78
Monotonic single-index models to assess drug interactions. Stat Med (2016) 0.75
Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies. Pharm Stat (2013) 0.75
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Cancer Prev Res (Phila) (2010) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24
A three-dimensional model to analyze drug-drug interactions. Antiviral Res (1991) 6.58
What is synergy? Pharmacol Rev (1989) 6.08
Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat (2007) 1.78
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30
A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics (2006) 1.28
Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res (1990) 1.15
Monotone smoothing with application to dose-response curves and the assessment of synergism. Biometrics (1990) 1.11
In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model. Cancer Chemother Pharmacol (1999) 0.91
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) (2009) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer (2009) 1.61
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60
Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst (2010) 1.59
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol (2002) 1.50
Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer (2006) 1.45
Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). Cancer Causes Control (2003) 1.39
Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer (2006) 1.36
Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res (2011) 1.33
Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. Cancer Prev Res (Phila) (2012) 1.33
Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog (2010) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) (2008) 1.32
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res (2012) 1.32
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther (2007) 1.29
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol (2012) 1.28
A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics (2006) 1.28
Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope (2005) 1.27
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. Cancer Res (2006) 1.24
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res (2008) 1.23
Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res (2002) 1.22
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer (2008) 1.21
A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res (2010) 1.21
Akt activation correlates with adverse outcome in tongue cancer. Cancer (2005) 1.20
A simulation study for comparing testing statistics in response-adaptive randomization. BMC Med Res Methodol (2010) 1.20
Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer (2011) 1.18
Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol (2004) 1.18
Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res (2006) 1.17
Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer (2004) 1.16
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res (2009) 1.15
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res (2013) 1.14
Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis (2006) 1.14
Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev Res (Phila) (2008) 1.13
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) (2011) 1.13
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer (2011) 1.12
Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol (2012) 1.11
Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res (2007) 1.08
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res (2011) 1.08
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol (2009) 1.08
Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res (2006) 1.06
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol (2012) 1.06
GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res (2002) 1.05
Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res (2004) 1.05
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res (2011) 1.05
A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One (2009) 1.03
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther (2010) 1.03
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis (2010) 1.01
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One (2011) 1.00
The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev (2006) 1.00
Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One (2012) 1.00
Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res (2004) 1.00
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst (2003) 1.00
The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. Ann Thorac Surg (2003) 0.99
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res (2007) 0.99
Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol (2015) 0.99